Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Moderate Buy” from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has received an average rating of “Moderate Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $20.00.

Several research firms have weighed in on ANRO. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Wedbush downgraded Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $29.00 to $4.00 in a research note on Wednesday, October 23rd. Stifel Nicolaus decreased their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Robert W. Baird dropped their price target on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Rodman & Renshaw lowered Alto Neuroscience from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 23rd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its position in shares of Alto Neuroscience by 619.2% in the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock valued at $49,000 after buying an additional 3,715 shares during the last quarter. Jane Street Group LLC bought a new stake in Alto Neuroscience in the 3rd quarter valued at $124,000. MetLife Investment Management LLC acquired a new stake in Alto Neuroscience during the 3rd quarter valued at $146,000. JPMorgan Chase & Co. boosted its position in Alto Neuroscience by 543.4% during the third quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company’s stock worth $278,000 after purchasing an additional 20,536 shares during the period. Finally, Rhumbline Advisers boosted its position in Alto Neuroscience by 24.4% during the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock worth $108,000 after purchasing an additional 5,008 shares during the period.

Alto Neuroscience Stock Performance

ANRO opened at $4.30 on Friday. The company has a fifty day moving average price of $4.24 and a two-hundred day moving average price of $8.27. Alto Neuroscience has a 52 week low of $3.56 and a 52 week high of $24.00. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last posted its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.05. On average, sell-side analysts forecast that Alto Neuroscience will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.